Vac­cine mak­er North­west Bio claims it's in the home­stretch for its man­u­fac­tur­ing ex­pan­sion in the UK

While the last 2 years have been a roller coast­er for Mary­land-based vac­cine mak­er North­west Bio­ther­a­peu­tics — high­light­ed by a $250,000 fine from the SEC, years op­er­at­ing as a pen­ny stock play­er with big ques­tions about a can­cer drug years in a piv­otal study — the biotech says it is still mov­ing ahead with its ex­pan­sion plans in the UK.

North­west filed its ap­pli­ca­tion for a li­cense to pro­duce at its newest Saw­ston site, where the first phase of the fa­cil­i­ty has been built out and the next step will in­clude an on-site in­spec­tion by the Med­i­cines and Health­care Prod­ucts Reg­u­la­to­ry Agency.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.